Several inhibitors targeting multiple receptor tyrosine kinases (TKIs) implicated in the pathogenesis of sarcomas including ES were also identified [52,53], including regorafenib, which is being evaluated in combination with chemotherapy (NCT02085148/2013-003579-36; NCT04055220/REGOSTA; 2021-005061-41/INTER-EWING-1; Table 2). Here, NTRK1 is linked to sarcoma.